Live attenuated bacteria of the species Actinobacillus pleuropneumoniae
US6013266A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Apr 9, 1998 |
| Grant date | Jan 11, 2000 |
| Priority date | — |
| Expiry date | Apr 9, 2018 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12R2001/01
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to live attenuated bacteria of the genus Actinobacillus pleuropneumoniae that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus Actinobacillus pleuropneumoniae. In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagonostic tests for the selective diagnosis of Actinobacillus pleuropneumoniae infections and to diagnostic tests discriminating between Actinobacillus pleuropneumoniae field strain and vaccine strains.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.